Amgen's CEO says he's 'confident' their $28B deal with Horizon can close despite FTC lawsuit

Drew Armstrong

Executive Editor

A day after federal antitrust authorities sued to stop Amgen’s $28 billion takeover of Horizon Therapeutics, Amgen’s CEO said he still expects the deal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amgen's CEO says he's 'confident' their $28B deal with Horizon can close despite FTC lawsuit

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

Exclusive: Can AI replace animal testing? A new biotech launches to find out

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Am­gen's CEO says he's 'con­fi­den­t' their $28B deal with Hori­zon can close de­spite FTC law­suit

Executive Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Amgen's CEO says he's 'confident' their $28B deal with Horizon can close despite FTC lawsuit